(1R,4R)-5-(4-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-3-fluorobenzyl)-2-oxa-5-azabicyclo[2.2.1]heptane | 1186334-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (1R,4R)-5-(4-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-3-fluorobenzyl)-2-oxa-5-azabicyclo[2.2.1]heptane
• 英文别名: 7-{2-fluoro-4-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]phenyl}-3-(1H-indazol-4-yl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidine；(1R,4R)-5-[[3-fluoro-4-[3-(1H-indazol-4-yl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]phenyl]methyl]-2-oxa-5-azabicyclo[2.2.1]heptane
• CAS: 1186334-30-4
• 化学式: C₃₀H₂₄FN₇O
• 分子量: 517.565
• InChiKey: UEMMXLHHQNSAQG-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (1R,4R)-2-氧杂-5-氮杂双环[2.2.1]庚烷 、 4-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-3-fluorobenzaldehyde 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 (1R,4R)-5-(4-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-3-fluorobenzyl)-2-oxa-5-azabicyclo[2.2.1]heptane
  参考文献：
  名称：

  Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity

  摘要：

  Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.

  DOI：

  10.1021/jm1007566

文献信息

• Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
  申请人：Levin Jeremy Ian

  公开号：US20100029657A1

  公开（公告）日：2010-02-04

  Compounds of formula A: and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.

  描述了化学式A的化合物及其药学上可接受的盐，这些化合物可选择性地抑制Raf激酶活性，并用于治疗由Raf激酶介导的疾病。
• Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity
  作者：Xiaolun Wang、Dan M. Berger、Edward J. Salaski、Nancy Torres、Minu Dutia、Cilien Hanna、Yongbo Hu、Jeremy I. Levin、Dennis Powell、Donald Wojciechowicz、Karen Collins、Eileen Frommer、Judy Lucas

  DOI：10.1021/jm1007566

  日期：2010.11.11

  Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.